Development of non-invasive and accurate methods to track cell fate after delivery will greatly expedite transition of embryonic stem (ES) cell therapy to the clinic. In this protocol, we describe the in vivo monitoring of stem cell survival, proliferation and migration using reporter genes. We established stable ES cell lines constitutively expressing double fusion (DF; enhanced green fluorescent protein and firefly luciferase) or triple fusion (TF; monomeric red fluorescent protein, firefly luciferase and herpes simplex virus thymidine kinase (HSVtk)) reporter genes using lentiviral transduction. We used fluorescence-activated cell sorting to purify these populations in vitro, bioluminescence imaging and positron emission tomography (PET) imaging to track them in vivo and fluorescence immunostaining to confirm the results ex vivo. Unlike other methods of cell tracking, such as iron particle and radionuclide labeling, reporter genes are inherited genetically and can be used to monitor cell proliferation and survival for the lifetime of transplanted cells and their progeny.
INTRODUCTION
Embryonic stem (ES) cells are capable of differentiation into any somatic cell type of the human body and have the potential for unlimited self renewal 1 . As a result, these cells have been regarded as a leading candidate source for donor cells in regenerative medicine. However, before ES cells can be safely applied clinically, it is important to understand the in vivo behavior of ES cells and their derivatives. Conventional histology and reporter genes, such as green fluorescent protein (GFP) and b-galactosidase (LacZ), do not allow for longitudinal imaging of cells that have been injected into animals because these methods need animal sacrifice and at best only provide a 'snapshot' of the biological fate of transplanted cells 2 . Recent advances in the field of molecular imaging have made it possible to non-invasively track transplanted cells over time 3 . These modalities, include physically attaching labels to cells as in the case of iron particles, radionuclide probes and quantum dots, or introducing reporter genes into cell lines to obtain the cellmediated generation of reporter probes 4 .
Traditional methods of imaging cell delivery in vivo have typically relied on physical cell labeling, as these modalities provide a straightforward approach to visualizing transplanted cells in living subjects 5, 6 . Physical cell labeling is completed before cell administration and can be accomplished with superparamagnetic iron oxide (SPIO) particles for magnetic resonance imaging (MRI) 7 , nanoparticle labeling for fluorescent imaging 8, 9 or radionuclide labeling for single positron emission computed tomography (SPECT) or positron emission tomography (PET) 10 . Physical cell labeling allows high spatial resolution (MRI) and high sensitivity (SPECT or PET) imaging and is best used to track the in vivo localization of cells in the hours to days after delivery. However, a common drawback these methods share is their reliance on physical labels. SPIO and radionuclide probes are diluted with cell division and are not capable of tracking cell proliferation, especially when cells misbehave as in the case of ES cell-derived teratoma formation 11 . SPIO agents further suffer from the unique problem of being taken up by macrophages after donor cell death (which may continue to produce signal even after cell death), and hence cannot be used to accurately monitor longterm cell survival and behavior 12 . By comparison, SPECT or PET tracers lose signal because of radioisotope decay. A typical PET radioisotope such as F-18 has a half-life of only 110 min and can only be used to image cells in the hours immediately following cell delivery 13 . Other isotopes such as 99m Tc and 111 In have halflives on the order of 6 h and 2.8 d, respectively, and can be used to image cells for several hours to close to a week 14, 15 . However, in these studies, because cells are exposed to longer periods of radioactivity, impairment of cellular proliferation and differentiation may be an issue.
In contrast with physical cell-labeling modalities, reporter gene imaging is well suited for longitudinal imaging of cell survival. In this type of imaging, a gene coding for the synthesis of a detectable protein is introduced into a target cell line or tissue by viral or nonviral vectors. Examples of commonly used reporter genes include firefly luciferase (Fluc) and herpes simplex virus thymidine kinase (HSVtk), which can be detected by bioluminescence imaging (BLI) and PET, respectively 4 . Reporter genes can be inserted after a constitutive promoter such as ubiquitin, or after a tissue specific promoter such as myosin light chain in the case of cardiomyocytes 16 . BLI has a sensitivity on the order of 10 À15 -10 À17 mol per liter, whereas the sensitivity of PET is 10 À10 -10 À11 mol per liter and MRI has a sensitivity of only 10 À3 -10 À5 mol per liter 4 . It is important to note that, because active transcription of the reporter gene is a prerequisite for synthesis of the reporter protein, only cells that are alive yield positive imaging signals. Several studies have shown that BLI signals correlate robustly with cell numbers both in vitro and in vivo 17, 18 . Hence, changes in signals following cell administration can be used as indicators of cell engraftment or cell death. In addition, because the reporter gene integrates into the host cell's chromosome after stable transfection or transduction, the reporter gene is passed on from the mother cell to daughter cell. Genetic inheritance of the reporter gene thus permits monitoring
of donor cell proliferation (e.g., ES cell-derived teratoma formation). Finally, genomic and proteomic studies have shown that reporter genes do not significantly affect ES cell viability, proliferation or differentiation 19, 20 .
Using BLI and PET reporter gene imaging, our laboratory has successfully monitored the survival, proliferation and migration of transplanted ES cells 17, 21, 22 and their derivatives, such as cardiomyocytes 23 , endothelial cells 11, 24 and neural stem cells 25 over a prolonged period without necessitating animal sacrifice. We have also monitored immunogenic response against ES cell engraftment in syngeneic, allogeneic and xenogenic transplantation models 21, 22 . As reporter genes can be inserted after any promoter, this approach can also be used to monitor expression of target genes in developmental pathways and disease models. Our group has successfully applied BLI in this manner to investigate the patterns of STAT3 expression in embryoid body formation 26 and to track plasmidmediated transgene expression for short hairpin RNA interference therapy in C2C12 myoblasts 27 .
For delivery of the reporter gene, our group has employed both a double fusion (DF) construct containing enhanced green fluorescent protein (eGFP) and Fluc and a triple fusion (TF) construct containing monomeric red fluorescent protein (mRFP), Fluc and HSVtk (Fig. 1a) . When stably integrated into the genome of the cells, these constructs permit the longitudinal tracking of transfected cells using a multimodality imaging approach. Specifically, eGFP and mRFP reporter genes facilitate fluorescence microscopy and fluorescence activated cell sorting (FACS) of GFP/RFP positive cells, whereas the Fluc and HSVtk reporter genes allow for cell monitoring by BLI and PET, respectively. Interaction of Fluc with its substrate D-luciferin produces low intensity light (2-3 eV) that is detected by an ultrasensitive cooled charge-coupled device (CCD) camera for cell localization (Fig. 1b) . The reporter protein HSVtk phosphorylates its substrate, the PET reporter probe 9-4-[ 18 F]fluoro-3-(hydroxylmethylbutyl) guanine ([ 18 F]-FHBG), to produce high-energy photons (511 keV). These photons are then captured by the PET camera for cell localization (Fig. 1b) in a manner identical to radiotracer based PET imaging. The advantage of reporter gene PET imaging over radiotracer labeled PET imaging is that constitutive expression of the reporter protein HSVtk allows for longitudinal tracking of cell survival and localization without the constraint of label decay.
The choice of whether to use physical cell labeling or reporter gene modalities for in vivo imaging of transplanted cells depends on the subject of investigation, timeline of study, equipment available at a given institution and evaluation of the advantages and disadvantages of each technique (Fig. 2) . However, it is important to note that the use of separate imaging modalities, such as MRI, PET, SPECTor BLI is not mutually exclusive. Multimodality imaging approaches may minimize the potential drawbacks of using each imaging modality alone and a tailored combination of two or more techniques may be the best approach for a given experiment.
Reporter gene imaging suffers from several drawbacks. First, derivation of stable DF and TF reporter gene positive cell lines typically takes 3-6 weeks weeks, whereas preparation for iron particle or radioactive probe labeling can be completed within hours. Second, the spatial resolution of common reporter gene modalities such as PET or BLI is close to 1 mm 3 or 3 mm 3 , respectively, whereas MRI has a spatial resolution of 25- 28 and cytolytic T cells in humans 29 . Third, the introduction of reporter genes has the potential to alter cellular genome and phenotype.
This protocol details how reporter gene imaging may be used to monitor the engraftment, survival and proliferation of transplanted ES cells. We hope it may be used in conjunction with other imaging technologies such as MRI and radiotracer based techniques to answer a wide range of biological questions.
Experimental design
Generation of DF/TF constructs and stable ES cell lines. The DF and TF lentiviral vectors can be constructed using the conventional molecular cloning techniques based on restriction enzymes, For general information on cloning techniques, refer Wu et al. 30 . We have used a constitutive ubiquitin promoter to replace the cytomegalovirus (CMV) promoter to reduce potential transgene silencing after extended cell culture 31 . For precipitation and concentration of the lentiviral particles, we use PEG-it Lentivirus Concentration Solution, which results in lower toxicity to the transduced ES cells as compared with concentration by ultracentrifugation. The choice of cell type depends on the focus of specific studies and whether the cells are suitable for stable cell line generation. Our laboratory has generated several DF and TF mouse and human ES cell lines, such as the mouse D3 and human H7, H9 and HES2 lines using the protocol described below. In our experience, mouse ES cells are easier to form undifferentiated colonies on the mouse embryonic fibroblast (MEF) feeder layer from FACS sorted single cells compare to human ES cells, and are thus more easily isolated from surrounding MEFs. We therefore typically transduce mouse ES cells on feeder layers and human ES cells under feeder-free conditions to eliminate any contamination from GFP/RFP positive MEFs. Using a multiplicity of infection (MOI) of 10 usually gives rise to the highest transduction efficiency for ES cells. The optimal MOI for other type of cells should be experimentally determined. When transducing ES cells, colony sizes of 200-400 cells/colony usually yield the highest transduction efficiency. If the ES cell colonies are too large, cells that are compacted in the center will not be readily transduced. Successful transduction can be verified by observing the GFP/RFP positive cells under a fluorescence microscope and the approximate transduction efficiency can be calculated by counting GFP/RFP positive and negative cells using flow cytometry. Generally a transduction efficiency of 30%-40% is sufficient for FACS and subsequent subculture. Slightly lower transduction efficiency is tolerable but needs a higher number of starting cells for sorting. We recommend cryopreserving some of the ES cells derived from the first round of FACS sorting and expansion for any future experiments. A second round of FACS sorting for GFP/RFP after the initial subculture is needed to further isolate a highly purified population of cells that are positive for GFP/RFP. After each round of sorting, some ES cell colonies may differentiate. Therefore, isolated mouse and human ES cells should be seeded on a MEF feeder layer and only colonies that are characterized by typical ES cell morphologies 32, 33 (refractive Immunostaining of Mac-3 for macrophages (eI, eIII) and Prussian blue for iron (eII, eIV) was counterstained with hematoxylin and nuclear fast red, respectively. High numbers of macrophages loaded with iron particles were found between muscle bundles. Scale bars ¼ 100 mm (eI, eIII) and 20 mm (eII, eIV). (f) Immunofluorescence staining of green fluorescent protein (GFP) for transplanted hESC-ECs, CD31 for microvasculature of hind limb and Mac-3 for macrophages at 4 weeks after transplantation, n ¼ 15, ± standard deviation. Owing to poor ES cell survival, no GFP + hESC-ECs were detected near iron-containing macrophages. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) (blue). Scale bar ¼ 20 mm. The animal protocols were approved by the Administrative Panel on Laboratory Animal Care of Stanford University.
appearance, defined boundaries and high nuclear-to-cytoplasm ratio within individual cells) should be subcultured. The highly purified DF/TF ES cells that expanded from the second round of sorting can be directly transplanted into experimental animals.
BLI and PET imaging. After establishing the DF/TF stable cell lines, in vitro BLI of Fluc positive cells on culture plates can be used to show if the Fluc transgene is functional. This assay will also confirm that BLI signals (plotted in units of maximum photons per s per cm 2 per sr (steridin)) correlate with cell numbers (Fig. 3a,b) . For transplanting ES cells into animals, the DF/TF ES cells can be trypsinized and collected as a single cell suspension. For in vivo imaging, the minimum number of cells detectable by BLI is B100-500 cells 34 and 1,000 cells per mm 3 for small animal PET imaging 35 . However, this detection threshold number can vary depending on the robustness of the promoter or enhancer element used to drive the reporter gene, the specific cell type and the amount of reporter probe used in each study. Typically our laboratory has used anywhere from thousands to millions of cells for purposes of injection and longitudinal monitoring of cell survival. Although there is no 'set' amount of D-luciferin or [ 18 F]-FHBG to administer to animals for BLI or PET imaging, respectively, delivery of inadequate reporter probe may compromise visualization of signal. Our laboratory has successfully imaged cell survival using a D-luciferin concentration of 375 mg kg À1 animal body weight for BLI and an [ 18 F]-FHBG activity of B200 mCi for microPET 36 . Animals that receive transplantations of non-transduced cells can be used as negative controls to determine the background BLI and PET signals. Afterwards, cells can be imaged non-invasively at any time-point after transplantation. In the case of ES cells, acute cell death following transplantation will be observed for the first 1 or 2 weeks, after which the remaining cells will proliferate and eventually cause the formation of teratomas. To monitor this bimodal process, our laboratory has traditionally imaged animals receiving transplantation of ES cell or ES cell derivatives at days 0, 2, 7, 10 and 14 and weekly thereafter for up to 6 months using BLI 23 . By comparison, we have typically taken microPET images at weekly intervals because of the high cost of [ 18 F]-FHBG production. In both BLI and microPET, increases in signal indicative of cell proliferation and teratoma formation can be observed as early as the second or third weeks after ES cell transplantation. The choice of anatomical location to inject cells depends on the focus of investigation. The majority of our experiments have revolved around myocardial injection because of our group's focus on cardiovascular disease 17, 23 . However, we have also used other sites, such as the gastrocnemius muscle 11, 21, 22 , the kidney capsule and subcutaneous injection 21, 37 . Certain organs such as the kidney and the heart need technical expertise for injection. For general tracking of cell survival in vivo, we recommend delivering cells to an easily accessible site such as the leg muscle or subcutaneous regions of the dorsal flank.
Operation of BLI and PETreporter gene imaging needs the use of equipments, such as a Xenogen In Vivo Imaging System (IVIS) and a MicroPET scanner (see equipment set up below). For operating these machines the manufacturer's instruction should be followed. For BLI, users must have access to the software program Living Image (Caliper Life Sciences, Hopkinton, Massachusetts) and be able to administer D-luciferin by intra-peritoneal injection to study animals. The use of the PET scanner requires training in radiation safety as [ 18 . Lipofectamine 2000 (Invitrogen, cat. no. 11668-019) . 5Â PEG-it Lentivirus Concentration Solution (System Biosciences, cat. no.
LV810A-1)
. EQUIPMENT SETUP Xenogen In Vivo Optical Imaging System The Xenogen optical imaging system consists of a light impermeable box with a mounted CCD camera. The system is fully calibrated using a standard 'hockey-puck' with scintillation cocktails with four small point sources of light. The xenogen system is controlled using Living Image software.
MicroPET scanner The small animal PET scanners should be set up following the manufacturer's instructions. The two scanners we use are eXplore Vista (GE Healthcare) and microPET Rodent R4 (Concorde Microsystems).
PROCEDURE Production of eGFP-Fluc DF and mRFP-Fluc-HSVtk TF lentiviruses TIMING 4 d
1| Seed B5 Â 10 6 HEK293FT cells in 10 ml of growth medium per 100-mm tissue culture dish and incubate at 37 1C, 5% CO 2 overnight.
2|
The next day, mix 12 mg of DF or TF plasmid, 8 mg of psPAX2 packaging plasmid and 4 mg of pMD2G envelope plasmid with 1.5 ml of opti-MEM I medium in a 15-ml conical centrifuge tube.
3|
In a separate 15-ml centrifuge tube add 6 ml of lipofectamine 2000 to 1.5 ml of opti-MEM I medium. Mix gently and incubate for 5 min at room temperature (20-25 1C) .
4|
Combine the plasmid/opti-MEM I medium mixture with the diluted lipofectamine 2000 and mix gently. Incubate for 20 min at room temperature.
5| Add the total volume (B3 ml) of plasmid:lipofectamine 2000 mixture dropwise into the 100-mm dish containing HEK293FT cells, incubate for 6 h at 37 1C, 5% CO 2 . Aspirate the transfection medium and add 10 ml of fresh HEK293FT growth medium and incubate at 37 1C, 5% CO 2 .
6| After 24 h of incubation, collect the culture medium (B10 ml) in a 50-ml conical centrifuge tube and add 10-ml fresh HEK293FT growth medium to the cells. Incubate the collected B10 ml of culture medium containing the viral particles at 4 1C overnight. ! CAUTION The supernatant contains packaged lentiviruses that will infect human cells. Please follow the institution's biosafety level 2 procedures when handling lentiviruses.
7|
The next day, collect the culture medium (B10 ml) again and combine it with the B10 ml of medium collected the previous day. Centrifuge for 15 min at 3,000g, 4 1C. Pass the total volume of supernatant (B20 ml) through a 0.45-mm filter and mix with 5 ml of 5Â PEG-it Lentivirus Concentration Solution. Incubate at 4 1C overnight. m CRITICAL STEP Incubation of the viral particles-PEG-it mixture should be longer than 12 h at 4 1C.
' PAUSE POINT The viral particles-PEG-it mixture can be incubated at 4 1C for up to 2 weeks. ' PAUSE POINT The lentiviruses can be stored at À80 1C for up to 3 months. 14| Aspirate the culture medium from the transduced ES cells and wash the cells with 1-2 ml of PBS. Add 300 ml of cell dissociation buffer per well and incubate at 37 1C for 2-5 min. m CRITICAL STEP Long incubation time will damage the cells. Monitor the cells under a light microscope to avoid over digestion. Proceed to step 15 when the cells start to detach from one another.
Lentivirus transduction of ES cells TIMING 3-5 d 9|
15| Add 2 ml of mouse ES medium or mTeSR-1 per well to neutralize the cell dissociation buffer. Gently resuspend the ES cell colonies into single cells using a 2-ml serological pipette. Add another 3 ml of mouse ES medium or mTeSR-1 to dilute the cell dissociation buffer. Pass the B5 ml of cell suspension through a 70-mm cell strainer and collect into a 50-ml centrifuge tube. m CRITICAL STEP Resuspend the cells gently to avoid cell death, observe under a light microscope to verify single cell suspension.
16| Centrifuge the cell suspension for 2 min at 500g, 4 1C. Aspirate the supernatant and add 5 ml of PBS to wash the cells by gentle swirling or pipetting.
17| Centrifuge for 2 min at 500g, 4 1C, aspirate the supernatant. Add 1 ml of PBS and propidium iodide buffer (10 ml/2-3 Â 10 5 cells), resuspend the cells gently and transfer into a 5-ml round-bottom tube, incubate on ice.
18| Sort GFP (DF) or RFP (TF) positive cells with a sterile fluorescence activated cell sorter. Set the sorting gate specifically for green fluorescence with a 488-nm laser for GFP and red fluorescence with a 638-nm laser for RFP, respectively. Following sorting, adjust the concentration of the sorted cells to greater than 50,000 ml À1 and seed 1 ml of cells onto the prepared MEF feeder cells from Step 13. Add 10 ml of antibiotic/antimycotic solutions to the well and culture the cells for 36-48 h, 37 1C, 5% CO 2 . Then, every 24 h, aspirate the old medium and add 1 ml of mouse ES medium or mTESR-1 until the colony size reaches at least 300-500 cells; these are now ready for subculturing. This should take about 6-9 d. 20| Under a fluorescence microscope, mark the GFP/RFP positive ES cell colonies with an objective marker. Pick the marked colonies with a glass needle and transfer them with a p200 Gilson pipette into the gelatin-coated well containing the MEF feeder cells from Step 19 and 1 ml of mouse ES medium or 1 ml of mTESR-1. m CRITICAL STEP Only pick GFP or RFP positive colonies with typical ES cell morphology to avoid contamination from differentiated cells. For a typical ES cell morphology see references 32 and 33.
21| Keep culturing the picked ES cell colonies, remove the old medium and refresh with 1 ml of mouse ES medium or mTeSR-1 everyday. Passage the cells every 5-7 d following routine ES cell passaging protocols (for ES cell passaging protocols, refer to Bryjia et al. 32 and Lerou et al. 33 ) until the cells reach confluence in at least 2 wells of the 6-well tissue culture dish.
22|
Of the wells containing expanded GFP/RFP positive ES cell colonies derived from step 21, keep at least one well for further expansion. Maintain and passage the cells in this well following routine ES cell culture and passaging protocols. This is to preserve the GFP/RFP positive ES cell colonies for future sorting. 25| Seed a series of serially diluted cells (e.g., a twofold dilution of 1 Â 10 6 cells) in 0.5 ml of mouse ES medium or mTeSR-1 in a 24-well tissue culture dish and culture for 2 h at 37 1C, 5% CO 2 (see Fig. 3a ).
26| Aspirate the culture medium and add 0.4 ml of 4.5 mg ml À1 D-luciferin in PBS to cover the cells and immediately image the cells with a Xenogen IVIS (see EQUIPMENT SETUP).
27| Plot the bioluminescence data in units of maximum photons per s per cm 2 per sr for a fixed region of interest (ROI) against cell number using Microsoft Excel or another graphing software program (see Fig. 3b ).
Transplantation of DF or TF ES cells into animals TIMING 1-3 h 28| Repeat
Step 24, count the cells and transfer the appropriate number of cells (our laboratory generally aims for at least 1 Â 10 6 cells per injection site although we have used as few as 1 Â 10 3 cells depending on cell availability) in a 15-ml centrifuge tube; centrifuge the cells for 2 min at 800g, room temperature.
29| Aspirate the supernatant, add 5-50 ml of PBS and resuspend the cells gently with a P200 Gilson pipette. Immediately incubate the cells on ice.
Step 30 and Step 31 should then be carried out within 30 min. m CRITICAL STEP The lower the volume of PBS the better survival rate for the cells. Higher density gives rise to better survival of the transplanted ES cells.
30| Anesthetize the animal designated for transplantation following the approved animal study protocol of the institution. In our laboratory, we have used a constant flow of 1-2% (for mice) or 2-3% (for rat) isoflurane vapor in oxygen to anesthetize the animal. For optical BLI imaging, shave the animal at the site of injection if the animal is not nude. ! CAUTION Please adhere to the approved institutional animal protocols when handling mice or rats.
31| Inject the volume of cells suspended in 5-50 ml of PBS into the appropriate engraftment site (e.g., subcutaneously) of the animal. The animal can be imaged immediately after cell transplantation or several hours/days later. ? TROUBLESHOOTING (iv) Continue to image the animal at regular intervals. We normally image the animals at days 2, 4 and 7 and weekly thereafter (see Fig. 3c ). m CRITICAL STEP For consistent results, weigh the animal before each imaging session and inject 375 mg kg À1 body weight D-luciferin.
(v) Analyze the images using Igor image analysis software, which is available from the WaveMetrics. 43 (can be downloaded free of charge at http://www.amide.sourceforge.net). Draw a ROI to encircle the appropriate area containing signal. After signal quantification, convert PET units to counts ml À1 min À1 using a calibration constant obtained from a cylindrical phantom with a known activity of 18 F. Assuming a tissue density of 1 g ml À1 , ROI counts ml À1 min À1 can be converted to counts g À1 min À1 . This value can subsequently be divided by tracer activity at the time of imaging to calculate the injected dose per gram of tissue (%ID g À1 ). The overall formula is [mean ROI signal Â cylinder calibration factor] / [activity at time of imaging]. (vi) Image the animal at regular intervals for the duration of the experiment. We usually image at a weekly interval until animal sacrifice or study endpoint (Fig. 4) . As with BLI, cell survival can potentially be monitored by microPET for the lifetime of the animal.
TIMING
Steps ? TROUBLESHOOTING Troubleshooting advice can be found in Table 1 .
ANTICIPATED RESULTS
Stably transduced DF and TF cells do not significantly differ from untransduced counterparts in terms of cell viability, proliferation or differentiation 19, 20 . Our laboratory has routinely differentiated cells expressing DF or TF reporter genes into embryoid bodies (Ebs), cardiomyocytes, endothelial cells and neural stem cells (see refs. 11,17,23-,25) . After the establishment of stable DF or TF cell lines, imaging of cell survival following transplantation can be maintained for the duration of cell survival. As previously stated, estimates for the minimum number of cells detectable by BLI is B500 cells 34 and 1,000 cells per mm 3 for small animal PET imaging 35 . However, the detection sensitivity will likely vary depending on the robustness of reporter gene expression, amount of reporter probes administered, location of transplanted cells (for BLI), and degree of cell survival. Typically after the injection of undifferentiated ES cells, an acute period of cell death will be observed for the first week, reflected by a decrease in BLI signal. After this, an increase in signal will be observed because of cell proliferation and teratoma formation ( Fig. 2c and upper panel of Fig. 3c ). In our experience, the number of cells that are needed for teratoma formation will vary between the site of administration and whether the host is immunocompetent or immunodeficient. For immunodeficient hosts, we have been able to form tumors with as few as 500-1,000 cells 37 . In contrast to undifferentiated ES cells, injection of ES cell therapeutic derivatives, such as endothelial cells (Fig. 2c) and cardiomyocytes (Fig. 3c, lower panel) , undergo significant cell death after transplantation as reflected by a strong decrease in BLI signal over the first 4 weeks post surgery. (Figs. 2c,d and 3c ). In the case of ES-derived cardiomyocytes, we have observed stable engraftments after transplantation out to greater than 6 months 23 . However, these grafts constitute less than 1% of the original cells transplanted. For small animal PET imaging, DF cells are not appropriate for this modality because they do not carry the HSVtk reporter gene that allows uptake of the [ 18 F]-FHBG reporter probe (Fig. 4a) . Only TF stable cell lines that carry the HSVtk reporter gene should be used. After the administration of [ 18 F]-FHBG into animals, the tracer will be distributed to most of the tissues and clear gradually within an hour or so. Owing to the natural excretion route, background PET activity will generally be present in the liver, the kidney and the bladder region (Fig. 4a) . For transplanted ES cells, a significant increase in PET signals will be observed after 1 week of transplantation. We have also compared MRI and BLI imaging modalities in tracking the cell fate of undifferentiated DF ES cells and human ES cell-derived endothelial cells (hESC-ECs) after transplantation. Cell labeling with SPIO particles for MRI allowed for high resolution visualization of ES cell and hESC-EC localization after delivery. However, MRI was unable to accurately track longitudinal cell growth and proliferation. Although MRI detected teratoma formation by anatomical resolution (Fig. 2a) , the gradient-recalled echo (GRE) signal did not increase with ES cell growth and tumor development (Fig. 2b) . For differentiated hESC-ECs, MRI was similarly unable to detect longitudinal changes in cell survival. By contrast, BLI reporter gene imaging of the same animal accurately tracked ES cell survival and proliferation after cell administration (Fig. 2c) . As compared with GRE signal, which remained constant after cell delivery, the BLI signal of delivered ES cells exhibited a bimodal curve showing acute cell death after injection and subsequent proliferation (Fig. 2d) . for the persistent GRE signals observed (Fig. 2e) . Immunostaining confirmed the absence of transplanted GFP positive cells nearby iron-containing macrophages (Fig. 2f) . In summary, after establishment of stable DF or TF cell lines, imaging of ES cell survival after transplantation is possible for the duration of cell survival. Incorporation of these imaging modalities described here will allow investigators to study biologically relevant questions such as tumorigenicity, immunogenicity and differentiation.
